A Phase 1 interventional study of Fimasartan, Ketoconazole, Rifampicin in Essential Hypertension, sponsored by Boryung Pharmaceutical Co., Ltd. Completed. Open to male participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-10-08.
Sponsored by Boryung Pharmaceutical Co., Ltd · Phase 1 and Interventional
To evaluate the effect of ketoconazole and rifampicin on the pharmacokinetics of fimasartan.
527 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.
This study's enrollment of 24 is below the median of 166 across 449 interventional studies indexed under Essential Hypertension.
Browse Essential Hypertension studies →Boryung Pharmaceutical Co., Ltd is the lead sponsor of 139 studies on the registry; 23 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Fimasartan, Ketoconazole, Rifampicin
Fimasartan (1 day) Ketoconazole (3 days) Ketoconazole + Fimasartan (1 day) Rifampicin (9 days) Rifampicin + Fimasartan (1 day)
Cmax, AUClast, AUCinf, CL/F, Tmax, t1/2
Time frame: 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 32, (48, 56) h
No study locations are listed for this record.
This study is completed, as verified in Oct 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Boryung Pharmaceutical Co., Ltd